Taro Pharmaceutical Indus... (TARO)
NYSE: TARO
· Real-Time Price · USD
42.98
0.01 (0.02%)
At close: Jun 21, 2024, 9:59 PM
Revenue by Geography
| Period Ending | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 | Mar 31, 2016 | Mar 31, 2015 | Mar 31, 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Canada Revenue | 136.24M | 130.07M | 46.57M | 42.82M | 40.05M | 38.22M | 29.2M | 22.96M | 22.16M | 10.72M |
| Canada Revenue Growth | +4.75% | +179.27% | +8.77% | +6.91% | +4.78% | +30.90% | +27.16% | +3.64% | +106.65% | n/a |
| Israel Revenue | 46.14M | 47.91M | 8.4M | 8.28M | 8.76M | 7.29M | 7.25M | 5.96M | 8.14M | n/a |
| Israel Revenue Growth | -3.70% | +470.42% | +1.42% | -5.48% | +20.19% | +0.59% | +21.61% | -26.83% | n/a | n/a |
| Other Country Revenue | 27.5M | 6.69M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Country Revenue Growth | +311.17% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue | 363.06M | 376.68M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | -3.61% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 58.13M | 50.41M | 54.54M | 55.86M | 50.13M | 49.86M | 42.26M | 56.12M | 41.17M | 24.84M | 23.68M | 23.98M | 22.23M | 22.8M | 24.07M | 22.25M | 29.11M | 20.93M | 23.65M | 19.72M | 23.32M | 23.88M | 19.18M | 23.58M | 23.77M | 21.83M | 18.34M | 24.25M | 22.21M | 20.31M | 20.89M | 22.25M | 22.56M | 22.87M | 24.05M | 22.89M | 22.23M |
| Selling, General, and Administrative Revenue Growth | +15.31% | -7.57% | -2.37% | +11.44% | +0.54% | +18.00% | -24.71% | +36.30% | +65.75% | +4.89% | -1.22% | +7.83% | -2.47% | -5.30% | +8.21% | -23.58% | +39.07% | -11.50% | +19.95% | -15.45% | -2.35% | +24.49% | -18.65% | -0.81% | +8.91% | +19.02% | -24.36% | +9.20% | +9.32% | -2.75% | -6.14% | -1.37% | -1.33% | -4.91% | +5.04% | +2.98% | n/a |
| Research and Development Revenue | 20.48M | 13.59M | 14.32M | 16.14M | 16.31M | 12.91M | 11.52M | 11.51M | 14.89M | 14.2M | 12.49M | 12.95M | 16.59M | 14.08M | 16.55M | 12.93M | 15.8M | 15M | 15.54M | 13.44M | 20.51M | 14.73M | 14.65M | 13.35M | 20.31M | 17.46M | 18M | 14.66M | 19.88M | 18M | 14.85M | 17.92M | 19.95M | 17.94M | 18.73M | 14.54M | 23.86M |
| Research and Development Revenue Growth | +50.71% | -5.14% | -11.27% | -0.99% | +26.33% | +12.02% | +0.12% | -22.72% | +4.87% | +13.65% | -3.53% | -21.91% | +17.80% | -14.93% | +27.99% | -18.15% | +5.35% | -3.49% | +15.59% | -34.46% | +39.29% | +0.48% | +9.82% | -34.29% | +16.33% | -2.99% | +22.77% | -26.26% | +10.43% | +21.26% | -17.16% | -10.17% | +11.17% | -4.19% | +28.80% | -39.07% | n/a |